Proteins

Product Data Sheet

ATV041

Pathway:

Cat. No.: HY-152535 CAS No.: 2935937-67-8 Molecular Formula: $C_{25}H_{29}N_5O_5$ Molecular Weight: 479.53 Target: Others

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

Others

BIOLOGICAL ACTIVITY

Description ATV041 is an orally active Ibuprofen (HY-78131) and nucleotide analogue. ATV041 improves oral pharmacokinetic (PK) profile and tissue distribution with anti-mouse hepatitis virus (MHV) activity. ATV041 reduces viral load, tissue damage and virusinduced inflammation in a dose-dependent manner^[1].

IC₅₀ & Target Mouse hepatitis virus (MHV)^[1]

ATV041 inhibits CCoV, FIPV and TGEV with EC₅₀ values of 1.406 μ M, 7.34 μ M and 3.777 μ M, respectively^[1]. In Vitro

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo ATV041 (200 mg/kg; p.o.; single dose) is widely and rapidly distributes in plasma, liver, lung and kidney tissues^[1].

> ATV041 (10, 50 and 200 mg/kg; p.o.; single dose) inhibits virus replication in liver and lung in a dose-dependent manner. $ATV041\ down-regulates\ the\ expression\ of\ TNF-\alpha \boxtimes IL-1\beta \boxtimes IL-6\boxtimes IFN-\gamma and\ CXCL10\ inflammatory\ factors\ and\ improves\ tissue$ damage^[1].

Pharmacokinetic (PK) parameters of GS-441524 and Ibuprofen in SD rats^[1]

(GS-441524 and Ibuprofen are produced by hydrolysis of ATV041)

Analytes	Route	Dose (mg/kg)	T _{1/2} (h)	T _{max} (h)	C _{max} (μM/L)	AUC _{0-∞} (h•μM/L)	$MRT_{0-\infty}$ (h)	F (%)
GS-441524	p.o.	25.0	4.98±3.57	0.67±0.29	7.75±1.58	22.6±2.34	3.16±1.21	60.31±0.06
GS-441524	i.v.	5.0	2.81±3.28	0.08±0.00	5.67±0.57	7.51±0.85	1.28±0.139	-
Ibuprofen	p.o.	25.0	2.63±1.78	0.67±0.29	80.2±12	263±37	3.35±0.925	78.42±0.11
Ibuprofen	i.v.	5.0	1.58±0.82	0.03±0.00	41.8±3.12	67.1±4.39	1.57±0.294	-

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

SD rats^[1]. Animal Model:

Dosage:	5 or 25 mg/kg.			
Administration:	Oral gavage or intravenous injection; single dose.			
Result:	Showed an oral activity and efficacy.			
Animal Model:	BALB/c mice $^{[1]}$.			
Dosage:	10, 50 and 200 mg/kg.			
Administration:	Oral gavage; single dose.			
Result:	Improved tissue distribution and reduced viral load, tissue damage, virus-induced inflammation.			

REFERENCES

[1]. Zhou Q, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. Eur J Med Chem. 2023 Jan 10;249:115113.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA